These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 31393455)

  • 1. [Selective α2 agonists in the treatment of glaucoma: neuroprotective properties and impact on ocular blood flow].
    Kurysheva NI
    Vestn Oftalmol; 2019; 135(3):113-120. PubMed ID: 31393455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Selective α2-agonists in the treatment of glaucoma: pharmacology, efficacy and safety].
    Kurysheva NI
    Vestn Oftalmol; 2019; 135(2):144-150. PubMed ID: 31215546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alpha-2 adrenergic receptor agonists are neuroprotective in experimental models of glaucoma.
    Wheeler LA; Woldemussie E
    Eur J Ophthalmol; 2001; 11 Suppl 2():S30-5. PubMed ID: 11592528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of systemic beta-blocker therapy on the efficacy and safety of topical brimonidine and timolol. Brimonidine Study Groups 1 and 2.
    Schuman JS
    Ophthalmology; 2000 Jun; 107(6):1171-7. PubMed ID: 10857839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of brimonidine tartrate on retinal blood flow in patients with ocular hypertension [corrected].
    Carlsson AM; Chauhan BC; Lee AA; Leblanc RP
    Am J Ophthalmol; 1999 Dec; 128(6):697-701. PubMed ID: 10612505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of alpha-2 agonists in neuroprotection.
    Wheeler L; WoldeMussie E; Lai R
    Surv Ophthalmol; 2003 Apr; 48 Suppl 1():S47-51. PubMed ID: 12852434
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brimonidine: a new alpha2-adrenoreceptor agonist for glaucoma treatment.
    Greenfield DS; Liebmann JM; Ritch R
    J Glaucoma; 1997 Aug; 6(4):250-8. PubMed ID: 9264305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence on the neuroprotective properties of brimonidine in glaucoma.
    Scuteri D; Bagetta G; Nucci C; Aiello F; Cesareo M; Tonin P; Corasaniti MT
    Prog Brain Res; 2020; 257():155-166. PubMed ID: 32988470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adrenergic and imidazoline receptor-mediated responses to UK-14,304-18 (brimonidine) in rabbits and monkeys. A species difference.
    Burke J; Kharlamb A; Shan T; Runde E; Padillo E; Manlapaz C; Wheeler L
    Ann N Y Acad Sci; 1995 Jul; 763():78-95. PubMed ID: 7677389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of brimonidine tartrate on retinal blood flow in patients with ocular hypertension.
    Carlsson AM; Chauhan BC; Lee AA; LeBlanc RP
    Am J Ophthalmol; 2000 Mar; 129(3):297-301. PubMed ID: 10704543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertension. Brimonidine Study Group 2.
    LeBlanc RP
    Ophthalmology; 1998 Oct; 105(10):1960-7. PubMed ID: 9787370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. α2-Adrenergic modulation of the glutamate receptor and transporter function in a chronic ocular hypertension model.
    Jung KI; Kim JH; Park CK
    Eur J Pharmacol; 2015 Oct; 765():274-83. PubMed ID: 26300392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brimonidine. A review of its pharmacological properties and clinical potential in the management of open-angle glaucoma and ocular hypertension.
    Adkins JC; Balfour JA
    Drugs Aging; 1998 Mar; 12(3):225-41. PubMed ID: 9534022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The ocular hypotensive effect and safety of 0.2% brimonidine].
    Yu M; Li Y; Ge J
    Yan Ke Xue Bao; 2001 Dec; 17(4):235-8. PubMed ID: 12567513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Use of brimonidine 0.2% in treatment of glaucoma or ocular hypertony after poorly tolerated beta-blocker treatment].
    Titouamane S; Baudouin C
    J Fr Ophtalmol; 2002 Jun; 25(6):568-75. PubMed ID: 12223942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brinzolamide plus brimonidine for the treatment of glaucoma: an update.
    Chew SK; Skalicky SE; Goldberg I
    Expert Opin Pharmacother; 2014 Nov; 15(16):2461-71. PubMed ID: 25267543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brimonidine tartrate for the treatment of glaucoma.
    Oh DJ; Chen JL; Vajaranant TS; Dikopf MS
    Expert Opin Pharmacother; 2019 Jan; 20(1):115-122. PubMed ID: 30407890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Melatonin and its analog 5-methoxycarbonylamino-N-acetyltryptamine potentiate adrenergic receptor-mediated ocular hypotensive effects in rabbits: significance for combination therapy in glaucoma.
    Crooke A; Huete-Toral F; Martínez-Águila A; Martín-Gil A; Pintor J
    J Pharmacol Exp Ther; 2013 Jul; 346(1):138-45. PubMed ID: 23591996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy and safety of brimonidine 0.2% compared with timolol 0.5% in glaucoma: a randomized clinical trial on Taiwanese patients.
    Chen MJ; Chou JC; Hsu WM; Liu JH
    J Chin Med Assoc; 2003 May; 66(5):276-81. PubMed ID: 12908569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in intraocular pressure and ocular perfusion pressure after latanoprost 0.005% or brimonidine tartrate 0.2% in normal-tension glaucoma patients.
    Liu CJ; Ko YC; Cheng CY; Chiu AW; Chou JC; Hsu WM; Liu JH
    Ophthalmology; 2002 Dec; 109(12):2241-7. PubMed ID: 12466165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.